Press Releases

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.

Date	Title and Summary	Additional Formats
Toggle SummaryMay092016	Fate Therapeutics Reports First Quarter 2016 Financial Results Phase 1/2 Clinical Trial of ProTmune™ for Prevention of Acute GvHD and CMV Infection to Begin Enrollment in mid-2016 Adaptive NK Cell Cancer Immunotherapy to be Featured at Innate Killer Summit in mid-May Immuno-Regulatory CD34 + Cell Therapy Abstract Accepted for Presentation at American Read All »	View HTML Fate Therapeutics Reports First Quarter 2016 Financial Results 34.2 KB
Toggle SummaryMay022016	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2016 Financial Results on May 9, 2016 SAN DIEGO, May 02, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2016 Financial Results on May 9, 2016 11.7 KB
Toggle SummaryApr052016	Fate Therapeutics to Present at the Needham & Company 15th Annual Healthcare Conference SAN DIEGO, April 05, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be Read All »	View HTML Fate Therapeutics to Present at the Needham & Company 15th Annual Healthcare Conference 11.5 KB
Toggle SummaryMar032016	Fate Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results ProTmune™ Investigational New Drug Application for Prevention of Acute GvHD and CMV Infection Cleared by FDA in January 2016 Phase 1/2 Clinical Trial of ProTmune to Commence Enrollment in mid-2016 Data Updates for All Preclinical Adoptive Immunotherapy Programs Expected in 1H16 SAN DIEGO, Read All »	View HTML Fate Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results 38.1 KB
Toggle SummaryFeb252016	Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2015 Financial Results on March 3, 2016 SAN DIEGO, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2015 Financial Results on March 3, 2016 11.9 KB
Toggle SummaryFeb212016	Fate Therapeutics to Present Preclinical Data for ProTmune™ at 2016 BMT Tandem Meetings Poster Presentation to Highlight Anti-Tumor Properties of Ex Vivo Programmed Donor T Cells Phase 1/2 Clinical Trial of ProTmune in Mobilized Peripheral Blood HCT to Commence Enrollment in Mid-2016 SAN DIEGO, Feb. 21, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML Fate Therapeutics to Present Preclinical Data for ProTmune™ at 2016 BMT Tandem Meetings 17.1 KB
Toggle SummaryFeb032016	Fate Therapeutics to Present at Leerink Partners 5th Annual Global Healthcare Conference SAN DIEGO, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be Read All »	View HTML Fate Therapeutics to Present at Leerink Partners 5th Annual Global Healthcare Conference 10.8 KB
Toggle SummaryJan262016	Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV Infection Multi-Center, Randomized, Controlled Phase 1/2 Clinical Trial in Mobilized Peripheral Blood HCT to be Initiated in Mid-2016 Read All »	View HTML Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for ProTmune for Prevention of Acute GvHD and CMV Infection 16.8 KB
Toggle SummaryJan062016	Fate Therapeutics to Present at Biotech Showcase 2016 SAN DIEGO, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Read All »	View HTML Fate Therapeutics to Present at Biotech Showcase 2016 10.8 KB
Toggle SummaryDec072015	Fate Therapeutics Provides Update on Adoptive Immunotherapy Programs for Hematopoietic Cell Transplantation Supportive Interim Data from ProHema® PUMA Study Demonstrate the Therapeutic Potential of Programmed Donor Cells Clinical Development Strategy to Focus on Prevention of Life-Threatening Complications in Mobilized Peripheral Blood HCT ProTmune™ to Advance into Phase 1/2 Clinical Trial for Read All »	View HTML Fate Therapeutics Provides Update on Adoptive Immunotherapy Programs for Hematopoietic Cell Transplantation 27.5 KB
Toggle SummaryDec032015	Fate Therapeutics to Present at Oppenheimer & Co. 26th Annual Healthcare Conference SAN DIEGO , Dec. 3, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced today that Scott Wolchko , President and Chief Executive Read All »	View HTML Fate Therapeutics to Present at Oppenheimer & Co. 26th Annual Healthcare Conference 16.6 KB
Toggle SummaryNov052015	Fate Therapeutics to Present Strategy for the Development of Off-the-Shelf Cancer Immunotherapies at ASH 2015 Proprietary Pluripotent Cell Platform for Engineered Adoptive Immunotherapies to be Highlighted During Two Poster Sessions Read All »	View HTML Fate Therapeutics to Present Strategy for the Development of Off-the-Shelf Cancer Immunotherapies at ASH 2015 61.9 KB
Toggle SummaryNov052015	Fate Therapeutics to Present Preclinical Data for ProTmune(TM) at ASH 2015 Annual Meeting First-in-Human Clinical Trial to Prevent Acute Graft-versus-Host Disease and Severe Infections Planned for 2016 Poster Presentations to Highlight Preclinical Findings and Potential Therapeutic and Pharmacoeconomic Value Propositions in HCT SAN DIEGO, Nov. Read All »	View HTML Fate Therapeutics to Present Preclinical Data for ProTmune(TM) at ASH 2015 Annual Meeting 61.9 KB
Toggle SummaryNov032015	Fate Therapeutics Reports Third Quarter 2015 Financial Results Pluripotent Cell Platform for Generating Off-the-Shelf Cancer Immunotherapies to be Presented at ASH 2015 Annual Meeting First-in-Human Clinical Trial of PROTMUNE™ to Prevent Acute GvHD and Severe Infections Planned for 2016 Reached 70% of Target Enrollment for PROHEMA® PUMA Study SAN Read All »	View HTML Fate Therapeutics Reports Third Quarter 2015 Financial Results 27.9 KB
Toggle SummaryOct292015	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2015 Financial Results on November 3, 2015 SAN DIEGO, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, today announced that the Company will host a conference call and Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2015 Financial Results on November 3, 2015 10.9 KB